Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis

BACKGROUND: In CARE-MS II (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis; NCT00548405), alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved health-related quality of life (HRQL) outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a)...

Descripción completa

Detalles Bibliográficos
Autores principales: Arroyo, Rafael, Bury, Denise P, Guo, Jennifer D, Margolin, David H, Melanson, Maria, Daizadeh, Nadia, Cella, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350196/
https://www.ncbi.nlm.nih.gov/pubmed/31144568
http://dx.doi.org/10.1177/1352458519849796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350196/
https://www.ncbi.nlm.nih.gov/pubmed/31144568
http://dx.doi.org/10.1177/1352458519849796

Ejemplares similares